Form 4: Gilead Sciences Director Harish Manwani Reports Stock Transactions

Director Harish Manwani reports acquisition of restricted stock units and stock options, along with disposition of common stock.

Summary

• Harish Manwani, a director of Gilead Sciences, Inc., reported transactions involving the company's stock on May 7, 2025.
• Manwani acquired 1,516 restricted stock units (RSUs) under the 2022 Equity Incentive Plan, which vested immediately.
• He also acquired 6,809 shares via a non-qualified stock option with an exercise price of $98.9, which vested immediately and expires on May 7, 2035.
• Additionally, he disposed of 296 shares of common stock at a price of $98.9 per share.
• Following these transactions, Manwani beneficially owns 14,093 shares of Gilead Sciences common stock and 6,809 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as the filing represents routine transactions. The acquisition of RSUs and stock options is a positive sign, but the disposal of shares tempers the overall sentiment.

Positives

• The acquisition of RSUs and stock options indicates Manwani's continued investment and confidence in Gilead Sciences.
• The immediate vesting of the RSUs and stock options suggests a strong incentive alignment with the company's performance.

Negatives

• The disposal of 296 shares, while a small portion of his holdings, could be interpreted negatively by some investors.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key personnel.

Stakeholder Impact

• The transactions may have a minor impact on shareholder sentiment, depending on how investors interpret the insider's actions.

Key Dates

Keywords

Gilead Sciences, Harish Manwani, Stock Options, RSUs, Director, Form 4, Equity Incentive Plan, Stock Transaction